guidance.fyi
Company, ticker, metric, guidance, or anything said

Concalls & earnings callsDishman Carbogen Amcis Limited

Every summarised call, newest first. Latest is Q1 FY27, held 17 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Open full brief →

Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.

MetricThis quarterChangeFive-quarter trend
Income from Operations₹677.6 Cr-4%
EBITDA₹60 Cr—
CDMO Segment Revenue₹534.3 Cr—
Marketable Molecules Revenue₹143.2 Cr—
Latest guidance
  • Single-digit revenue growth for FY27.
  • EBITDA margin similar to last year for FY27.
  • Indian entity revenue to grow 30-35% in FY27.
  • Double-digit growth expected in French entity and India operations for FY28-29.
  • Net debt expected to be around CHF 140-150 million for FY27 (excluding promoter infusion).
Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹682.34 Cr+4.8% YoY-13.5% QoQ₹4.63 CrTurned profitable YoY-86% QoQ₹0.30Turned positive YoY-85.8% QoQ
Q2 FY25₹789.04 Cr+34.5% YoY+50.6% QoQ₹33.09 CrTurned profitable YoYTurned profitable QoQ₹2.11Turned positive YoYTurned positive QoQ
Q1 FY25₹523.78 Cr-27.6% YoY-20% QoQ₹-77.57 CrTurned loss-making YoYLoss widened QoQ₹-4.95Turned negative YoYLoss/share widened QoQ
Q4 FY24₹654.71 Cr+5.8% YoY+0.6% QoQ₹-69.92 CrLoss narrowed YoYLoss widened QoQ₹-4.46Loss/share narrowed YoYLoss/share widened QoQ
Q3 FY24₹651.09 Cr+1.8% YoY+11% QoQ₹-59.63 CrTurned loss-making YoYLoss widened QoQ₹-3.80Turned negative YoYLoss/share widened QoQ
Call history
  • Q1 FY27Positive tone

    Despite a soft revenue quarter, management is focused on sales force expansion, tech transfers to India, and a significant debt refinancing to improve margins, projecting an optimistic future.

    Income from Operations
    ₹677.6 Cr-4%
    EBITDA
    ₹60 Cr
    Pharmaceuticals & HealthcareVerified brief5 guidance items